CareDx, Inc. (CDNA)
NASDAQ: CDNA · Real-Time Price · USD
19.93
+0.49 (2.52%)
At close: Feb 18, 2026, 4:00 PM EST
19.93
0.00 (0.00%)
After-hours: Feb 18, 2026, 4:10 PM EST
CareDx Employees
As of December 31, 2024, CareDx had 650 total employees, including 644 full-time and 6 part-time employees. The number of employees increased by 7 or 1.09% compared to the previous year.
Employees
650
Change (1Y)
7
Growth (1Y)
1.09%
Revenue / Employee
$550,766
Profits / Employee
$108,386
Market Cap
1.03B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 650 | 7 | 1.09% | 644 | 6 |
| Dec 31, 2023 | 643 | -95 | -12.87% | 635 | 8 |
| Dec 31, 2022 | 738 | 93 | 14.42% | 727 | 11 |
| Dec 31, 2021 | 645 | 170 | 35.79% | 633 | 12 |
| Dec 31, 2020 | 475 | 89 | 23.06% | 456 | 19 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| OPKO Health | 2,997 |
| Neogen | 2,974 |
| Myriad Genetics | 2,700 |
| NeoGenomics | 2,200 |
| Fulgent Genetics | 1,313 |
| GeneDx Holdings | 1,000 |
| Veracyte | 824 |
| Castle Biosciences | 823 |
CDNA News
- 12 hours ago - CareDx to Participate in the Raymond James 47th Annual Institutional Investors Conference - Business Wire
- 3 days ago - Baron Discovery Fund Q4 2025: Winners, Laggards, Buys & Sells - Seeking Alpha
- 6 days ago - CareDx, Inc. (CDNA) Discusses AlloHeme Clinical Validation Data Review and Launch Timeline in AML and MDS Post-Cell Therapy Transcript - Seeking Alpha
- 6 days ago - CareDx Announces Clinical Validation Results for AlloHeme™, the First AI‑Powered NGS Surveillance Solution for AML and MDS Post‑Cell Therapy - Business Wire
- 8 days ago - CareDx to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 - Business Wire
- 15 days ago - CareDx to Present AlloHeme™ Pivotal Clinical Validation Data in Hematologic Cancer Relapse Detection at 2026 Tandem Meetings - Business Wire
- 22 days ago - CareDx to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference - Business Wire
- 5 weeks ago - CareDx Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results - Business Wire